A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer

Trial Profile

A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs MTL CEBPA (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man
  • Acronyms OUTREACH
  • Sponsors MiNA Therapeutics
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 13 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, no DLTs were reported to date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top